

Supplementary material

New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity

Jiale Yu ¹, Xiaoxia Mao ¹, Xue Yang ², Guiqin Zhao ¹ and Songtao Li ^{1,*}

¹ Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Materia Medica, Chengde Medical University, Chengde 067000, China; 15102526322@163.com (J.Y.); mao0505@163.com (X.M.); zhaoguiqin1971@sina.com (G.Z.)

² School of Basic Medical Sciences, Chengde Medical University, Chengde 067000, China; xyang_cdmu@163.com

* Correspondence: songtao-li@hotmail.com

Contents

| | |
|---|-------|
| Characterization of DOX-SS-Pyr and the PDCs..... | S1-S7 |
| <i>In vitro</i> cytotoxicity of the ^L T7-SS-DOX conjugate..... | S8 |




Figure S4. HPLC chromatogram of the ^LT7-SS-DOX conjugate




Figure S5. ESI MS of the ^LT7-SS-DOX conjugate, molecular weight for [C₇₄H₉₆N₁₆O₂₂S₂]: calculated, 1624.6; found, 813.3 [M + 2H]²⁺




Figure S6. HPLC chromatogram of the ^DT7-SS-DOX conjugate




Figure S7. ESI MS of the ^DT7-SS-DOX conjugate, molecular weight for [C₇₄H₉₆N₁₆O₂₂S₂]: calculated, 1624.6; found, 813.4 [M + 2H]²⁺




Figure S8. *In vitro* cytotoxicity of ^LT7-SS-DOX against cells. Data were presented as mean ± SD (n = 3), **p* < 0.05; ***p* < 0.01 and ****p* < 0.001 versus LO2 cells group.